Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
Open Access
- 14 March 2020
- Vol. 12 (3), 685
- https://doi.org/10.3390/cancers12030685
Abstract
The long-term efficacy of the Epidermal Growth Factor Receptor (EGFR)-targeted antibody cetuximab in advanced colorectal cancer (CRC) patients is limited by the emergence of drug-resistant (persister) cells. Recent studies in other cancer types have shown that cells surviving initial treatment with targeted agents are often vulnerable to alterations in cell metabolism including oxidative stress. Vitamin C (VitC) is an antioxidant agent which can paradoxically trigger oxidative stress at pharmacological dose. Here we tested the hypothesis that VitC in combination with cetuximab could restrain the emergence of secondary resistance to EGFR blockade in CRC RAS/BRAF wild-type models. We found that addition of VitC to cetuximab impairs the emergence of drug persisters, limits the growth of CRC organoids, and significantly delays acquired resistance in CRC patient-derived xenografts. Mechanistically, proteomic and metabolic flux analysis shows that cetuximab blunts carbohydrate metabolism by blocking glucose uptake and glycolysis, beyond promoting slow but progressive ROS production. In parallel, VitC disrupts iron homeostasis and further increases ROS levels ultimately leading to ferroptosis. Combination of VitC and cetuximab orchestrates a synthetic lethal metabolic cell death program triggered by ATP depletion and oxidative stress, which effectively limits the emergence of acquired resistance to anti-EGFR antibodies. Considering that high-dose VitC is known to be safe in cancer patients, our findings might have clinical impact on CRC patients treated with anti-EGFR therapies.Funding Information
- Associazione Italiana per la Ricerca sul Cancro (20236, 21091, 21923, Accelerator Award contract 22795, 20697, 17707, 20685)
- Horizon 2020 (635342-2 MoTriColor, TRANSCAN-2 JTC 2014 contract no. TRS-2015-00000060 INTRACOLOR, TRANSCAN-2 JTC 2014 TACTIC)
- European Research Council (724748 – BEAT)
- Ministero della Salute (RC 2019)
This publication has 48 references indexed in Scilit:
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal CancerCancer Discovery, 2018
- The Genetic/Non-genetic Duality of Drug ‘Resistance’ in CancerTrends in Cancer, 2018
- Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibitionNature, 2017
- Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathwayNature, 2017
- The cellular origins of drug resistance in cancerNature Medicine, 2016
- A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancerInvestigational New Drugs, 2015
- Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancersNature Communications, 2015
- Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent EvolutionCancer Discovery, 2014
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Cetuximab for the Treatment of Colorectal CancerThe New England Journal of Medicine, 2007